OSE 127

Drug Profile

OSE 127

Alternative Names: Anti CD127 monoclonal antibody - OSE Immunotherapeutics; Anti interleukin-7 receptor-α monoclonal antibody - OSE Immunotherapeutics; Effi-7; IL-7 receptor antagonist - OSE Immunotherapeutics; Interleukin-7 receptor antagonist - OSE Immunotherapeutics; OSE-127

Latest Information Update: 30 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Effimune
  • Developer INSERM; OSE Immunotherapeutics; PX Therapeutics
  • Class Anti-inflammatories; Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Interleukin 7 receptor alpha subunit inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Acute lymphoblastic leukaemia; Inflammation; Transplant rejection; Ulcerative colitis
  • Research Sjogren's syndrome

Most Recent Events

  • 26 Oct 2017 OSE Immunotherapeutics plans a phase II trial for Ulcerative colitis by end-2018
  • 23 May 2017 OSE Immunotherapeutics extends its agreement with Selexis for clinical development of OSE 127
  • 27 Dec 2016 Effi-7 licensed to Servier Pharmaceuticals worldwide
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top